FDA Grants Fast Track Designation to Balixafortide Plus Eribulin for Metastatic Breast Cancer
Posted: Tuesday, April 24, 2018
On April, 19, 2018, the U.S. Food and Drug Administration granted Fast Track designation to Polyphor’s immuno-oncology candidate balixafortide (POL6326), in combination with eribulin, for the treatment of patients with HER2-negative metastatic breast cancer who failed to respond to at least two chemotherapeutic regimens in the metastatic setting.
Balixafortide, a highly selective CXCR4 antagonist, showed anticancer activity in a phase Ib proof-of-concept trial that included patients with metastatic breast cancer, according to a press release from the manufacturer. CXCR4 is a G-protein–coupled receptor that regulates the trafficking and homing of both cancer cells and cells of the patient’s immune system.
